JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M507238200 on October 31, 2005

J. Biol. Chem., Vol. 281, Issue 1, 508-517, January 6, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
281/1/508    most recent
M507238200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lane, M. C.
Right arrow Articles by Moore, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lane, M. C.
Right arrow Articles by Moore, S. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular Basis of the Interaction between the Flagellar Export Proteins FliI and FliH from Helicobacter pylori*{boxs}

Michael C. Lane{ddagger}1, Paul W. O'Toole{ddagger}§, and Stanley A. Moore{ddagger}2

From the Department of Biochemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E5, Canada, the §Department of Microbiology and Alimentary Pharmabiotic Centre, University College Cork, Western Road, Cork, Ireland, and {ddagger}Institute of Molecular Biosciences, Massey University, Palmerston North, New Zealand

Received for publication, July 5, 2005 , and in revised form, October 26, 2005.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Bacterial flagellar protein export requires an ATPase, FliI, and presumptive inhibitor, FliH. We have explored the molecular basis for FliI/FliH interaction in the human gastric pathogen Helicobacter pylori. By using bioinformatic and biochemical analyses, we showed that residues 1–18 of FliI very likely form an amphipathic {alpha}-helix upon interaction with FliH, and that residues 21–91 of FliI resemble the N-terminal oligomerization domain of the F1-ATPase catalytic subunits. A truncated FliI-(2–91) protein was shown to be folded, although the N-terminal 18 residues were likely unstructured. Deletion and scanning mutagenesis showed that residues 1–18 of FliI were essential for the FliI/FliH interaction. Scanning mutation of amino acids in the N-terminal 10 residues of FliI indicated that a cluster of hydrophobic residues in this segment was critical for the interaction with FliH. The interaction between FliI and FliH has similarities to the interaction between the N-terminal {alpha}-helix of the F1-ATPase {alpha}-subunit and the globular domain of the F1-ATPase {delta}-subunit, respectively. This similarity suggests that FliH may function as a molecular stator.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Helicobacter pylori is a Gram-negative microaerophilic bacterium that colonizes the human gastric mucosa and is associated with a number of gastric diseases (14). H. pylori motility is conferred by the production of multiple polar flagella and is essential for colonization and persistence by the pathogen (5, 6). The study of H. pylori flagellar protein export and flagellum assembly is relatively new; most of our knowledge of the bacterial flagellum comes from studies in Salmonella enterica serovar Typhimurium (7, 8). Comparison of known Salmonella flagellar genes with the H. pylori genome confirms the existence of H. pylori homologs for most flagellar proteins in Salmonella and Escherichia coli (9, 10). However, the regulation of several of these genes appears to be distinct from the Salmonella paradigm (10, 11). A two-hybrid study of H. pylori protein/protein interactions revealed a small number of expected flagellar protein interactions (12). Flagellar proteins not annotated in the H. pylori genome include regulators such as FlhC, FlhD, and FliK and the chaperones FliJ, FlgN, and FlgT. The distinctive regulation of H. pylori flagellar gene expression (911), the flagellar configuration (polar, sheathed), and the absolute requirement of motility for H. pylori pathogenesis make flagellar biogenesis an attractive candidate for molecular studies in this organism.

Flagellum secretion machines (7, 1315) contain a highly conserved flagellum-specific ATPase, FliI, essential for the secretion of flagellar hook and filament proteins. FliI and other export apparatus proteins are thought to associate with the flagellar basal body at the cell membrane (7, 1623). FliI from Salmonella is a 456-amino acid polypeptide that peripherally associates with the bacterial cytoplasmic membrane (22, 23). In the presence of ATP, Salmonella FliI forms hexamers and demonstrates positive cooperativity of ATP hydrolysis in vitro, and both activities are stimulated in the presence of anionic phospholipids (23). Salmonella FliI has also been shown to interact with FliH, a conserved flagellar export component that inhibits FliI enzymatic activity in vitro (2428).

Several studies (1618, 26) suggest that Salmonella FliI contains two domains, a poorly characterized N-terminal segment (amino acids 1–97) with secretion-specific functions and a C-terminal catalytic domain (amino acids 100–456) homologous to the catalytic domains of the {alpha}- and {beta}-subunits of F1-ATPase. Mutation of active site residues in the C-terminal domain of FliI are dominant negative for swarming motility (1618). Similar studies on the homologous InvC type III ATPase also demonstrated negative dominance of catalytic site mutations that were relieved on disruption of membrane localization of the ATPase (20, 21).

The interaction of FliI with FliH, a conserved component of the flagellar and type III secretion systems that inhibits FliI ATPase activity in vitro, has been studied in Salmonella (2427). An N-terminal FliI double mutant (R7C/L12P) was isolated from genetic screens that detected loss of swarming motility in vivo and acted in a recessive manner (26). This double mutant also failed to interact with FliH in vitro (26), suggesting individual residues in this segment of FliI were required for interaction with one or more components of the export apparatus, including FliH. However, further experiments were not carried out to verify and substantiate this preliminary observation. Furthermore, the extreme nature of the R7C/L12P double mutant suggested this mutation very likely prevented the FliI N terminus from folding into a structure capable of interacting with FliH. Nevertheless, truncated versions of Salmonella FliI purified from limited proteolysis experiments and containing residues 7–456 or 26–456 did not interact with FliH as judged by gel filtration chromatography (24), indicating the N terminus of FliI is largely responsible for interactions with FliH. These studies also indicated that Salmonella FliI was sensitive to clostripain proteolysis at amino acids 7, 26, 93, and 97, but the extent of FliI proteolysis was reduced in the presence of Salmonella FliH (24). FliH itself was not sensitive to clostripain proteolysis.

The domain structure of Salmonella FliH has been studied in some detail. Salmonella FliH forms an elongated dimeric structure in solution and a (FliH)2FliI complex forms with intact full-length FliI (27). A scanning deletion analysis of Salmonella FliH showed that residues 100–235 were required for interactions with FliI; residues 101–141 were required for FliH dimerization (likely via a coiled-coil segment); residues 70–100 were important for inhibition of FliI ATPase activity, and N-terminal residues contributed to binding to the flagellar chaperone FliJ (28). However, these studies do not suggest how FliH inhibits FliI ATPase activity, or what is the general role of FliH in flagellar protein secretion.

Our laboratories are studying flagellar biogenesis in the human gastric pathogen H. pylori as a model for the assembly of a polar sheathed flagellum (10, 19, 29, 30). Thus, we have recently identified the hook length control protein FliK (29) and a novel component that interacts with RpoN and FliH that is essential for flagellum assembly (30). We are also investigating individual flagellar components. The principal objective of this study was to extend our understanding of FliI structure and function based on analysis of the poorly characterized yet important N-terminal region of the molecule (residues 1–91 of H. pylori FliI). Furthermore, we hoped to gain insight into FliI function from analyzing the molecular details of the FliI/FliH interaction. A previously published Y2H partial interaction map of the H. pylori proteome demonstrated that a bait domain containing residues 1–258 of H. pylori FliH interacted with a prey domain containing residues 3–134 of H. pylori FliI (see Ref. 12 and pimhybrigenics.com). However, these studies did not indicate what residues in this fragment of H. pylori FliI were responsible for the interaction with FliH and, as in the Salmonella studies, did not indicate the molecular nature or absolute residue requirements of the interaction. Hence, biochemical confirmation and elaboration of the H. pylori FliI/FliH Y2H interaction (12) were necessary. In addition, no obvious sequence similarity exists between amino acids 1–25 of Salmonella FliI (reported to be required for FliH interaction) and the same region of H. pylori FliI or other FliI sequences.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Protein Sequence and Structure Analysis—PSI-BLAST searches (31, 32) for FliI homologs were conducted with standard parameters (www.ncbi.nlm.nih.gov/BLAST) using the H. pylori 26695 FliI protein sequence (HP1420; GenBankTM accession number 15646029). A selected group of FliI, type III ATPase, and F1-ATPase {alpha}- and {beta}-subunit sequences uncovered with the PSI-BLAST search were then prepared as a multiple sequence alignments with T-Coffee (supplemental Fig. S1) (33). In addition, three-dimensional structures are available for the bovine mitochondrial and Bacillus PS3 F1-ATPase {alpha}- and {beta}-subunit sequences (3436). Therefore, alignment of the FliI/type III ATPase N-domains was verified by using the superimposed structures of the four homologous F1-ATPase subunit N-domains extracted from the Protein Data Bank (www.rcsb.org) as calculated by LSQKAB in the CCP4 suite of programs (37). The most significant alignment to a known structure was to the {alpha}-subunit of Bacillus PS3 F1-ATPase (25.7% pairwise identity). The structures were visualized on a graphics work station using Turbo-Frodo (38). An homology model of FliI was constructed using Turbo-Frodo, based on the derived alignment and using the F1-ATPase subunit atomic coordinates as templates. The resultant FliI atomic model was energy-minimized using CNS (39). For amino acids 1–18 of FliI sequences given in Fig. S1, secondary structure was predicted using the PHD algorithm as implemented at the Predict-Protein server (40) (cubic.bioch.columbia.edu/predictprotein).

Bacteria and Recombinant Plasmids—DNA manipulation and transformation of E. coli DH5{alpha} or XL1-Blue was carried out as described by Sambrook and Russell (41). Gene fragments corresponding to FliH-(2–258), FliH-(55–258), FliH-(94–258), FliH-(117–258), FliI-(2–91), and FliI-(19–91) were isolated by PCR amplification of H. pylori 26695 chromosomal DNA (1–5 ng) by using the appropriate oligodeoxynucleotide primers (supplemental Table S1) (200 nm) in Pfu buffer (Fermentas), 0.2 mM of each dNTP, and 1 unit of Pfu DNA polymerase (Fermentas). Thermal cycling of the PCR was performed in a Bio-Rad MyCycler. Amplified DNA was purified with a QIAquick gel extraction kit (Qiagen), digested with BamHI and EcoRI, and ligated to BamHI/EcoRI-digested pGEX-6P3 glutathione S-transferase (GST)3 fusion protein expression vector (Amersham Biosciences). This vector contains a cleavage site for human rhinovirus 3C protease (PreScission Protease) between the GST tag and the insert. All recombinant proteins described in this study contain an additional N-terminal GPLGS sequence from the BamHI restriction site used in directional cloning of the gene fragments. Plasmids pGEX-6P3-FliI-(2–91) containing N-terminal point mutations were created using 5' primers with a single codon mismatch (see supplemental Table S1). Plasmids were purified from E. coli by using the Qiaprep Miniprep kit (Qiagen). Automated DNA sequencing was used to confirm either the correct DNA sequence or the presence of mutations deliberately introduced by PCR. Primers used in this study are listed in supplemental Table S1.

Overproduction and Purification of N-terminally GST-tagged Proteins—GST fusion proteins containing the truncated proteins FliH-(2–258), FliH-(55–258), FliH-(94–258), FliH-(117–258), FliI-(19–91) FliI-(2–91), and the eight FliI-(2–91) point mutants were purified from the soluble fractions of E. coli Rosetta cells according to the guidelines from Amersham Biosciences for the purification of GST fusion proteins. In brief, the cells were grown at 37 °C to an A600 between 0.4 and 0.6 and induced with 0.1 mM isopropyl {beta}-D-thiogalactoside. Following induction, the cells were grown at 25 °C overnight. Cells were harvested, frozen overnight, and lysed by a French press. The supernatant was clarified by centrifuging at 13,000 x g twice for 30 min and then incubated with glutathione-Sepharose for 3 h at 25 °C. The GST affinity tag was removed by adding PreScission protease to the glutathione-Sepharose-bound fusion protein or by adding protease once reduced glutathione was used to release the fusion protein from the resin. For the FliH proteins, they were further purified by anion exchange chromatography on Source Q resin at pH 8.5 followed by gel filtration chromatography in phosphate-buffered saline (PBS) buffer using a Superdex 200 analytical gel filtration column. FliI-(19–91) was purified on Source S followed by gel filtration on Superdex 75. FliI-(2–91) and mutants thereof were purified by glutathione-Sepharose affinity chromatography followed by hydrophobic interaction chromatography (HiTrap phenyl-HP) and finally gel filtration chromatography on Superdex 75.

Molecular Mass Estimation of Purified Proteins—Analytical gel filtration chromatography was used to estimate the molecular masses and respective oligomerization states of purified truncated FliI and FliH proteins. Analytical grade Superdex 75 and Superdex 200 columns from Amersham Biosciences were calibrated with a set of molecular mass standards. The calibration curve plotted is as follows: Kav = (Ve - V0)/(Vt - V0) versus the log10(molecular mass), where Ve is the sample elution volume; Vt is the total bed volume; and V0 is the column void volume. A line of best fit was fitted against the data points.

The Superdex 75 column had a void volume of 7.84 ml determined from the elution of blue dextran, and the total bed volume was 24 ml. The Superdex 75 column was calibrated with the following standards: albumin (Mr = 67,000, Ve = 9.84 ml), ovalbumin (Mr = 43,000, Ve = 10.88 ml), chymotrypsinogen A (Mr = 25,000, Ve = 12.80 ml), ribonuclease A (Mr = 13,700, Ve = 13.80 ml), aprotinin (Mr = 6,500, Ve = 15.73 ml), and vitamin B12 (Mr = 1355, Ve = 19.15 ml). The Superdex 200 column had a void volume of 8.04 ml determined from the elution of blue dextran, and the total bed volume was 24 ml. The Superdex 200 column was calibrated with the following standards: ferritin (Mr 440,000, Ve = 9.12 ml), catalase (Mr = 232,000, Ve = 10.64 ml), aldolase (Mr = 158,0000, Ve = 12.40 ml), albumin (Mr = 67,000, Ve = 14.00 ml), ovalbumin (Mr = 43,000, Ve = 15.12 ml), chymotrypsinogen A (Mr = 25,000, Ve = 16.80 ml), and aprotinin (Mr = 6,500, Ve = 19.01 ml).

GST Pulldown Assays—30 µl of glutathione-Sepharose was prepared by applying four washes of 3 volumes of PBS buffer and then mixing with 20 µg of GST-FliH-(2–258), GST-FliH-(55–258), GST-FliH-(94–258), GST-FliH-(117–258), or GST (all in PBS) for 30 min at room temperature. The protein-bound glutathione-Sepharose was then washed three times with 3 volumes of PBS. Then 4.8 µg of the purified FliI-(19–91), FliI-(2–91), or mutant FliI-(2–91) proteins was added to yield a 2:1 molar ratio of GST-FliH to FliI. The total volume was made to 200 µl with PBS. This mixture was allowed to incubate with gentle agitation for 30 min. The protein-bound glutathione-Sepharose was washed twice with 200 µl of PBS, separated by centrifugation, and boiled with SDS-PAGE loading buffer. The proteins were visualized with Coomassie Brilliant Blue on 15% SDS-polyacrylamide gels. Each well of the pulldown gel contained 20 µg of GST-FliH and 4.8 µg of truncated N-FliI (residues 2–91 or 19–91). Each gel series was repeated in triplicate and shown to be reproducible. Control pulldowns for all of the mutant proteins were conducted but are only shown for GST-FliH-(55–258) (bait) and FliI-(2–91) (prey) (Fig. 5). After GST tag removal, none of the purified prey proteins bound significantly to glutathione-Sepharose. Equivalent protein concentrations were evaluated by measuring protein UV absorbance at 276 nm in PBS buffer for each of the purified proteins based on their aromatic amino acid content.

Far-UV Circular Dichroism Spectroscopy—Far-UV circular dichroism spectra were recorded on a Pistar 180 spectrometer from Applied Photophysics. Spectra were recorded from 180 to 260 nm under a nitrogen atmosphere, and typically a total of 5 scans were recorded at 0.5 nm steps with entry and exit slits set at 4 nm. These scans were then averaged and smoothed to produce the spectra shown. Spectra were measured in 0.1-mm quartz cuvettes at a protein concentration of 0.5 mg/ml in PBS buffer.

Limited Proteolysis of Proteins—Trypsin or chymotrypsin was dissolved to a concentration of 0.1 mg/ml in 10% glycerol and PBS. Protease was added to 50 µg of the protein of interest (FliI-(2–91) or FliH-(2–258)) at a protease to target molar ratio of 1:1000, and the reaction was allowed to proceed for 60 min at room temperature. 10 µg of protein were removed after 5, 10, 20, 40, or 60 min and quenched with phenylmethylsulfonyl fluoride. The protein was visualized with Coomassie Brilliant Blue on SDS-polyacrylamide gels. Bands corresponding to protease digestion products were electroblotted onto polydivinylidine fluoride membranes and then subjected to micro-sequencing. We typically sequenced at least five residues to determine the position of protease cleavage. We also micro-sequenced several of the purified proteins used in this study to verify that their N termini were intact.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The N Terminus of H. pylori FliI Is Homologous to the F1-ATPase Oligomerization Domain—Previous studies have established significant amino acid sequence similarity between residues 100–430 of FliI and the catalytic domain of the F1-ATPase {beta}-subunit, indicating that the catalytic segments of these proteins descended from a common ancestor, and have a similar three-dimensional structure (1618, 21). However, the N-terminal domains of both FliI and the F1-ATPase catalytic subunits are also similar in size (~100 amino acids), and this prompted us to ascertain if the evolutionary relationship between these proteins extends to their respective N-terminal domains. PSI-BLAST searches (31, 32) of the nonredundant protein sequence data base demonstrated that residues 20–90 of H. pylori FliI are homologous to the oligomerization domain found in both the {alpha}- and {beta}-subunits of F1-ATPase (E-value scores ranging from 10-165 to 10-135). The alignments span residues 20–430 of FliI and residues ~20–430 of either the {alpha}- or {beta}-subunits of F1-ATPase. These results are summarized in a multiple sequence alignment containing FliI and type III ATPase sequences and F1-ATPase {alpha}- and {beta}-subunit sequences whose three-dimensional structures are known (34, 36) (supplemental Fig. S1). There are several invariant glycine residues in the alignment and a number of well conserved hydrophobic residues. The alignment was checked by building a model of residues 20–91 of H. pylori FliI using the structure of Bacillus PS3 F1-ATPase as the template (Fig. 1). The modeled structure indicated the presence of a conserved hydrophobic core in the predicted {beta}-barrel domain and that this domain is easily assembled into a hexameric ring structure based on the hexameric arrangement of the F1-ATPase subunit oligomerization domains in the F1-ATPase structure (34, 36). Independent secondary structure predictions of residues 20–90 of FliI (results not shown) also substantiate a {beta}-sheet structure for this segment. We also calculated the electrostatic surface potential of the model coordinates for residues 19–91 of hexameric H. pylori FliI (Fig. 1) because the FliI N-domain should be capable of interacting with anionic membrane phospholipids (2123). The modeled structure does indeed exhibit an electropositive surface potential on the surface most likely to contact the cell membrane (Fig. 1). Hence, we concluded that our alignment and structural modeling for residues 20–90 of FliI reliably predicts a {beta}-barrel structure for the N-domain of FliI.

Residues 1–18 of H. pylori FliI Likely Form an Amphipathic {alpha}-Helix—Residues 1–18 of H. pylori FliI are poorly conserved at the amino acid sequence level when compared with other FliI N-terminal sequences (supplemental Fig. S1) but do have a similar composition enriched in nonpolar and positively charged amino acids. Significantly, hydrophobic amino acids in the N-terminal segment of FliI have a similar periodicity to hydrophobic residues in the N-terminal segment of the F1-ATPase {alpha}-subunit that is known to form an amphipathic {alpha}-helix (supplemental Fig. S1) (42). The amphipathic nature of the FliI N-terminal segment suggests this segment is likely to form a short amphipathic {alpha}-helix (Fig. 1D). Secondary structure prediction indicated that residues 3–12 of H. pylori FliI have a high likelihood of forming an amphipathic {alpha}-helix. Other FliI N-terminal sequences also exhibit a high probability of helix formation (70–80%). Helical wheel plots of FliI N-terminal sequences, including those of H. pylori and Salmonella (shown in Fig. 1D), are highly suggestive of an amphipathic {alpha}-helix. These data demonstrate that the FliI N-terminal sequences are consistent with an amphipathic {alpha}-helical structure. The hydrophilic face of the predicted FliI N-terminal helix would exhibit a positive electrostatic surface, enabling it to potentially interact with anionic membrane lipids. Residues 13–18 of H. pylori FliI likely form a flexible loop, connecting the N-terminal helix to the predicted {beta}-barrel domain.

Expression and Characterization of FliI-(2–91) and FliI-(19–91)—To study the N-terminal domain structure of H. pylori FliI and to verify yeast two-hybrid interactions with FliH (12), we cloned a gene fragment corresponding to residues 2–91 of FliI (HP1420) from H. pylori 26695 genomic DNA as a GST fusion construct. The cloning and expression of truncated FliI N-terminal domains has not been attempted previously. GST fusion constructs of FliI-(2–91) purified from E. coli lysates were soluble and were purified to homogeneity (Fig. 2). The purified N-domain of FliI was deduced to be mostly folded from limited proteolysis experiments (Fig. 2) conducted in the presence of trypsin, although residues 2–18 were easily removed by trypsin treatment, as subsequent protein microsequencing of the major proteolysis product revealed a single cleavage site before Arg-19. In addition, the 1H-15N heteronuclear single quantum coherence (HSQC) NMR spectra of a 15N isotopically labeled FliI-(2–91) fragment4 demonstrated good chemical shift dispersion for the majority of the backbone amide N-H peaks. However, ~20 of the amide N-H peaks exhibited a narrow chemical shift distribution characteristic of a random coil structure. Far-UV circular dichroism analysis of FliI-(2–91) also indicated a considerable degree of folded structure (Fig. 2). But far-UV CD spectra of a synthetic peptide containing residues 2–14 of H. pylori FliI indicated a random coil structure.5 Therefore, we proposed that residues 1–18 of H. pylori FliI likely correspond to the ~20 random coil peaks in the 15N-1H HSQC spectrum and hence are unstructured in solution.



View larger version (22K):
[in this window]
[in a new window]
 
FIGURE 1.
Structural model of the H. pylori FliI N-domain residues 21–91 based on the alignment in Fig. S1. A, C-{alpha} coil trace drawn with Molscript-Raster3D (45, 46) is shown depicting the amino acid side chains of the hydrophobic core. Side chains are colored green for aliphatic amino acids, purple for proline, and gold for aromatic amino acids. B, ribbon diagram of the proposed H. pylori FliI-N domain hexamer, based on the arrangement of subunits in F1-ATPase. Drawn with Molscript-Raster3D (45, 46). C, electrostatic surface of the modeled FliI N-domain hexamer. Negative potential is red and positive potential is blue. Drawn with GRASP (47). D, helical wheel representation of the N-terminal sequences for H. pylori (starting at residue 2) and S. enterica FliI (starting at residue 5).

 
Analytical gel filtration profiles indicated that FliI-(2–91) eluted in two distinct peaks, indicating a mixture of FliI oligomers in solution. SDS-PAGE analysis of the gel filtration peak fractions verified that the same protein comprised each peak from the gel filtration experiments (results not shown). The elution volumes of the two FliI-(2–91) species on Superdex 75 corresponded to the molecular masses of 58.9 and 14.9 kDa, respectively, when compared against the elution volumes of several protein standards of known molecular mass (Fig. 2; see "Materials and Methods"). Repeating the same experiments on Superdex 200 (Fig. 6B) yielded two peaks with elution volumes consistent with molecular masses of 43.6 and 15.5 kDa. If we average the FliI-(2–91) molecular mass values determined from the two gel filtration experiments, then the predicted masses of the FliI-(2–91) oligomers observed in these two experiments are 51 and 15 kDa, respectively. As there is little doubt that the 15-kDa peak represents an FliI-(2–91) monomer (the amino acid sequence predicts a molecular mass of 10.3 kDa), the 51-kDa peak very likely corresponds to a trimer of FliI-(2–91) molecules. It is also not surprising that the apparent molecular mass of FliI-(2–91) predicted from gel filtration (15 kDa) is larger than the molecular mass predicted from the amino acid sequence (10.3 kDa) as residues 2–18 of FliI appear to be largely unstructured in solution and likely exist in an extended conformation. The fact that FliI-(2–91) appears capable of forming a trimeric structure in vitro may have implications for in vivo FliI assembly. Native full-length Salmonella FliI is known to form hexamers (23). We propose that the FliI-(2–91) and FliI-(19–91) trimers (see below) observed here likely correspond to one-half of a completely assembled FliI hexamer and hence represent an initial step in FliI hexamer assembly.

Because FliI-(2–91) was sensitive to limited proteolysis, we concluded that we could express a discrete domain of FliI containing residues 19–91, and this was verified by cloning, protein expression, and purification (Fig. 2). Again, we estimated the molecular mass of the FliI-(19–91) species by using both Superdex 200 and Superdex 75 analytical gel filtration media (Figs. 2C and 7B). In each case, FliI-(19–91) eluted as a single peak with a predicted molecular mass of 30 kDa. The calculated molecular mass of FliI-(19–91) is 8.3 kDa, and hence we concluded that FliI-(19–91) is also most likely a trimer in solution. The FliI-(19–91) domain was later used as a control in verifying interactions between FliI and FliH.



View larger version (32K):
[in this window]
[in a new window]
 
FIGURE 2.
A, purification of truncated H. pylori FliI and FliH molecules. 15% SDS-polyacrylamide gel stained with Coomassie Blue as follows: 1, molecular mass markers of 14.2, 20, 24, 29, 36, 45, 55, and 66 kDa; 2, FliI-(19–91); 3, FliI-(2–91); 4, FliH-(94–258); and 5, FliH-(117–258). B, limited proteolysis of FliI-(2–91). 15% SDS-polyacrylamide gel stained with Coomassie Blue as follows: 1, molecular weight markers of 14.2, 20, 24, 29, 36, 45, 55, and 66 kDa. Time course of limited trypsin proteolysis of FliI-(2–91) is as follows: 2, 0 min; 3, 5 min; 4, 10 min; 5, 20 min; 6, 40 min; 7, 60 min; and 8, authentic purified sample of FliI-(19–91). C, Superdex HR-75 elution profiles of purified wild type FliI-(2–91) and eight FliI N-terminal point mutants. Absorbance is recorded at 280 nm. Elution profiles of approximately equivalent loads of each mutant protein are shown. D, Superdex HR-75 elution profile of purified FliI-(19–91). Absorbance is recorded at 280 nm. E, far-UV CD spectrum of purified FliI-(2–91).

 
Characterization of Truncated FliH-(94–258) and FliH-(117–258) Proteins—Full-length H. pylori FliH (HP0353) was cloned by PCR amplification from H. pylori 26695 genomic DNA into a GST fusion protein expression vector. The full-length protein aggregated during subsequent attempts at purification. Hence, we pursued the identification of nonaggregative truncated FliH proteins to facilitate the study of interactions with FliI-(2–91). FliH-(55–258) was generated by limited trypsin digestion of full-length H. pylori FliH, and subsequent electroblotting and microsequencing of the major digestion products identified the N-terminal sequence of the major cleavage fragment. Upon further characterization and purification, it was evident that FliH-(55–258), although soluble and capable of interacting with FliI-(2–91) reproducibly, did not elute quantitatively from the gel filtration media. We therefore recloned N-terminally truncated versions of H. pylori FliH based on sequence conservation with other members of the FliH family.6 Two fragments were produced that should be capable of binding FliI, based on studies in Salmonella (28). These truncations are FliH-(94–258) and FliH-(117–258). Both truncated FliH proteins were purified to homogeneity (Fig. 2) and shown to be folded and monodisperse by analytical gel filtration and CD spectroscopy, respectively (Fig. 3). The far-UV CD spectra of FliH-(94–258) and FliH-(117–258) indicated that both proteins exhibited a high proportion of secondary structure, especially {alpha}-helix (Fig. 3B). However, H. pylori FliH-(117–258) had less helical content than FliH-(94–258) according to the magnitude of the trough at 215 nm in the CD spectra (Fig. 3B). In addition, the gel filtration elution volumes of the truncated FliH proteins were consistent with FliH molecular masses of ~58 or 45 kDa, respectively, based on calibration of the column with molecular standards of known mass (Fig. 3A; see "Materials and Methods"). The molecular masses of the FliH-(94–258) and FliH-(117–258) molecules derived from the amino acid sequences are 18.9 and 16.2 kDa, respectively. Hence, each of the truncated FliH molecules could exist either as trimers (56.7 and 48.6 kDa, respectively) or dimers (37.8 and 32.4 kDa, respectively). Although our gel filtration profile data taken alone are most consistent with a trimer of FliH molecules existing in solution, previous studies have shown that Salmonella FliH has a highly asymmetric dimeric structure and hence elutes on gel filtration media at volumes much smaller than those predicted by its apparent molecular mass and known dimeric structure (24, 26, 27). However, the truncated H. pylori FliH molecules used in this study are significantly smaller than Salmonella FliH (141 and 164 amino acids versus 235 amino acids) and may be considerably less aspherical in solution. We tentatively concluded that the solution structure of truncated H. pylori FliH is most likely an elongated dimer that migrates as an anomalously large species on gel filtration media (see "Discussion").



View larger version (18K):
[in this window]
[in a new window]
 
FIGURE 3.
Characterization of truncated FliH molecules. A, Superdex HR-200 elution profiles of FliH-(94–258) (black line) and FliH-(117–258) (gray line). Absorbance is recorded at 280 nm. B, far-UV CD spectra of FliH-(94–258) (black line) and FliH-(117–258) (gray line). CD samples are all 0.5 mg/ml in PBS.

 
FliI-(2–91), but Not FliI-(19–91), Interacts with FliH—When tested for interactions with the four truncated FliH proteins (full-length FliH and FliH fragments 55–258, 94–258, and 117–258), FliI-(2–91) interacted with all of them by GST pulldown assay, and FliI-(19–91) interacted with none of them (Fig. 4, and data not shown). This indicated that the major if not sole determinant for interactions with FliH resided within the first 18 residues of H. pylori FliI. This provided biochemical confirmation of the FliI/FliH interaction in H. pylori and validated the published H. pylori Y2H data (12).

We then investigated the FliI N-terminal sequence of 18 residues that allowed FliI-(2–91) to interact specifically with FliH. Because we have predicted that this segment of FliI is capable of forming an amphipathic {alpha}-helix, we hypothesized that a hydrophobic surface from such an FliI N-terminal helix could be the basis for interactions with FliH. We tested this by mutating most of the hydrophobic and positively charged amino acids to alanine or glutamate in residues 2–10 of H. pylori FliI. The proteins corresponding to these eight mutations were then expressed, purified, characterized, and tested for interactions with recombinant FliH (Fig. 5). GST pulldowns were conducted by using equimolar ratios of GST-FliH and each of the respective purified FliI-(2–91) mutant proteins. The GST pulldowns were highly reproducible, and the FliI-(2–91) mutants were then tested with each of the truncated FliH-(55–258), FliH-(94–258), and FliH-(117–258) proteins. All three truncated FliH proteins yielded essentially identical results with the purified FliI-(2–91) mutant proteins (FliH-(55–258) and FliH-(94–258) are shown in Fig. 5). Mutation of Leu-3 to Ala (L3A), Leu-6 to Ala (L6A), or Leu-10 to Ala (L10A) in FliI-(2–91) resulted in a dramatically weakened FliI-(2–91)/FliH interaction. A more drastic change of Leu-6 to Glu (L6E) also disrupted the interaction with FliH and was reproducibly weaker than the Leu to Ala mutations (Fig. 5). Additionally, we made Arg-9 to Ala (R9A), Arg-9 to Glu (R9E), Lys-7 to Ala (K7A), and Lys-4 to Ala (K4A) mutations and tested these for interaction with FliH. R9A, K7A, and K4A mutations interacted as well as wild type FliI-(2–91) with the recombinant FliH proteins (Fig. 5). However, a more drastic Arg-9 to Glu (R9E) mutation significantly weakened the FliI/FliH interaction. Hence, FliI principally interacts with FliH via three leucine residues at positions 3, 6, and 10 in the FliI sequence.

To ensure that the mutant FliI proteins had similar physical and chemical properties to the wild type FliI-(2–91), we examined each of the purified FliI mutants for their oligomerization properties as measured by elution profiles on a Superdex 75 analytical gel filtration column (Fig. 2B). The elution profiles of wild type FliI-(2–91) and the eight tested FliI N-terminal point mutants indicated that the mutant proteins behaved essentially the same as wild type FliI-(2–91) and eluted as a mixture of two peaks (assumed to be trimer and some monomer), although the relative ratio of the two peaks depended on the concentration of loaded protein. Far-UV CD spectra of the FliI-(2–91) point mutants were also indistinguishable from wild type FliI-(2–91).5 Hence, we concluded that the FliI N-terminal point mutations did not appreciably alter the structure of the FliI-(2–91) protein.

We then demonstrated that the FliI-(2–91)-FliH-(117–258) complex is very stable in solution and can be isolated and purified by gel filtration chromatography (Fig. 6). The complex appears to have a 1:1 ratio of FliI-(2–91) and FliH-(117–258) by SDS-PAGE analysis of the peak associated with the eluted complex (Fig. 6). The ratio of proteins visualized on the gel was verified by Coomassie staining of SDS gels of mixtures of known quantities of FliH and FliI (not shown). However, the elution volume of the FliH-FliI complex on Superdex 200 suggests a molecular mass of 1.3 x 105 Da, indicating that more than one copy of FliI-(2–91) and FliH-(117–258) is in the complex. Hence, the stoichiometry of the FliI-FliH complex appears to contain two FliH dimers along with three copies of FliI-(2–91), but this will have to be verified with other experimental approaches. The gel filtration peak associated with the FliI-FliH complex was collected, concentrated, and re-injected onto the Superdex 200 column and showed negligible dissociation into FliI-(2–91) and FliH-(117–258) during elution, indicating that this molecular association is very stable (Fig. 6). This complex does not form when the FliI-(2–91) L3A mutant is incubated with FliH-(117–258) or when FliI-(19–91) is incubated with FliH-(117–258) (Fig. 7).



View larger version (41K):
[in this window]
[in a new window]
 
FIGURE 4.
GST pulldown experiments of FliI-(19–91) and FliI-(2–91) with FliH-(55–258). Each experiment uses a GST-bait fusion protein, indicated beside the gel, and a purified prey protein. The presence of the prey protein in lane 8 is indicative of an interaction between the prey protein and the GST-bait protein. Coomassie Blue-stained 15% SDS-polyacrylamide gels of the GST pulldowns are shown as follows. A, GST-FliI-(2–91) with FliH-(55–258); B, GST-FliI-(19–91) with FliH-(55–258); C, GST-FliH-(55–258) with FliI-(2–91); and D, GST-FliH-(55–258) with FliI-(19–91). For each pulldown the corresponding lanes contain the following: lane 1, molecular weight markers 14, 18, 29, 43, 68, and 98 kDa; lane 2, purified prey protein; lane 3, glutathione-Sepharose incubated with prey protein; lane 4, blank; lane 5, GST and prey protein incubated with glutathione-Sepharose; lane 6, blank; lane 7, GST fusion bait protein incubated with glutathione-Sepharose; lane 8, GST fusion bait protein incubated with prey protein and glutathione-Sepharose.

 



View larger version (55K):
[in this window]
[in a new window]
 
FIGURE 5.
GST pulldowns of FliI-(2–91) mutants. 15% SDS-polyacrylamide gels stained with Coomassie Blue. All pulldowns contain 20 µg of A: GST-FliH-(55–258) (A) or GST-FliH-(94–258) (B) mixed with 4.8 µg of the appropriate FliI N mutant. C, input loads of 5 µg of the FliI N-mutant protein. Each gel in A–C contains 10 lanes labeled as follows: 19–91, FliI-(19–91); 2–91, wild type FliI-(2–91); L3A mutant; L6A mutant; R9A mutant; L10A mutant; L6E mutant; K7A mutant; R9E mutant; and K4A mutant.

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The purpose of this study was to improve our understanding of FliI structure and function by biochemically characterizing its N-terminal domain and to elucidate the detailed nature of the molecular basis of the interaction FliI with FliH. Our results support the view that the N terminus of FliI is organized into two functional regions as follows: residues 1–18 comprising a mostly unstructured segment that is absolutely necessary for interactions with FliH, plus a globular segment comprising residues 20–91 that is conserved in FliI, type III ATPase and F1-ATPase sequences (supplemental Fig. S1). Our alignment and homology modeling are consistent with residues 20–91 of FliI forming a globular domain very similar in structure to the N-terminal {beta}-barrel domain found in the F1-ATPase catalytic subunits. Far-UV CD spectral analysis confirmed that residues 2–91 of H. pylori FliI adopt a mostly folded structure in solution that is absent of significant helical content, consistent with our structural model. Structural modeling further suggests residues 20–91 of FliI may participate in the recognition and binding of anionic phospholipids (Fig. 1). Published studies on the InvC type III ATPase demonstrate that amino acids within the InvC N-terminal domain interact with membrane lipids (21).



View larger version (28K):
[in this window]
[in a new window]
 
FIGURE 6.
Characterization of the FliI-(2–91)-FliH-(117–258) complex by gel filtration chromatography. Purified proteins (2 mg/ml FliI and FliH in PBS buffer) were mixed and incubated for 30 min at room temperature prior to injection on a Superdex HR-200 analytical gel filtration column equilibrated in PBS buffer. The flow rate was 0.5 ml/min, and protein was detected by UV absorbance at 280 nm. A, Superdex HR-200 elution profile of a roughly 1:1 mixture of FliI-(2–91) and FliH-(117–258). B, Superdex HR-200 elution profile of purified FliI-(2–91). C, Superdex 200 elution profile of the re-concentrated peak 1 from A. D, Coomassie Blue-stained 15% SDS-PAGE analysis of the peak fractions from A.

 



View larger version (21K):
[in this window]
[in a new window]
 
FIGURE 7.
Characterization of a mutant FliI-(2–91)/FliH-(117–258) interaction and interaction of FliI-(19–91) with FliH-(117–258) by gel filtration chromatography. Buffer and incubation conditions were as in Fig. 6. A, Superdex HR-200 elution profile of a roughly 1:1 mixture of the L3A mutant of FliI-(2–91) and FliH-(117–258). B, Superdex HR-200 elution profile of purified FliI-(19–91). C, Superdex HR-200 elution profile of a roughly 1:1 mixture of FliI-(19–91) and FliH-(117–258).

 
Analytical gel filtration studies of FliI-(2–91) and FliI-(19–91) demonstrate that these truncated domains form oligomers in solution, and our data are most consistent with these domains predominantly associating into trimers in vitro. Therefore, in vitro trimerization of the FliI N-domain may reflect the first steps in hexamerization of full-length FliI (23). It is noteworthy that the corresponding N-terminal domain in the F1-ATPase {alpha}- and {beta}-subunits makes important subunit/subunit interactions and exhibits pseudo-hexameric symmetry in the functional F1-ATPase ({alpha}{beta})3 heterotrimer (3436).

The oligomerization properties of the H. pylori N-domain are in contrast with studies of full-length Salmonella FliI that indicate full-length FliI is largely a monomer in solution, except when ATP or anionic phospholipids are present (23, 27). Full-length H. pylori FliI is also monomeric in solution.5 Therefore, subunit/subunit interactions involving the truncated N-domain of FliI may behave differently in the context of the full-length FliI structure. In other words, the catalytic domain of FliI may impose structural constraints on subunit/subunit interactions involving the FliI N-domain, and these structural constraints may be sensitive to ATP binding in the catalytic domain.

Our work demonstrates that residues 1–18 of H. pylori FliI, although appearing unstructured in solution, are nevertheless absolutely required for interaction with FliH. That this segment likely forms an amphipathic {alpha}-helix upon interaction with FliH is supported by secondary structure predictions, helical wheel analysis, and mutagenesis results in combination with FliH binding studies. By using site-specific mutagenesis, we showed that three hydrophobic residues in the N-terminal FliI segment (leucine residues 3, 6, and 10) are absolutely required for the interaction with FliH. In contrast, most of the polar residues in this segment appear to have little effect on FliI-FliH complex formation. Hence, we predict that an FliI N-terminal amphipathic {alpha}-helix forms upon interaction with FliH and that a hydrophobic patch on this helix is critical for productive interactions with FliH. However, there is also a likely electrostatic component to the FliI/FliH interaction as mutation of Arg-9 to Ala did not noticeably affect the stability of the FliI-FliH complex, but the more drastic Arg-9 to Glu mutation significantly weakened complex formation.

Our studies provide significant new insight into to the FliI/FliH interaction. First, although work on the Salmonella FliI/FliH interaction implicated the N terminus of FliI, the experiments either involved use of a drastic FliI R7C/L12P double mutant or used two products purified from limited proteolysis experiments (residues 7–456 and 26–456) (24, 26). Our work demonstrates exactly what residues are important for the interaction in H. pylori FliI (a hydrophobic patch of leucine residues) by using scanning alanine mutagenesis of carefully characterized truncated domains of FliI in combination with a number of truncated recombinant FliH proteins. Incidentally, our results predict that residues 5–12 (5LTRWLTAL12) (hydropholic residues likely to interact with EliH indicated in bold) of Salmonella FliI likely make important contributions to the interaction with FliH (Fig. 1). We conclude that deletion of residues 1–7 of Salmonella FliI (24) likely impaired folding of residues 8–12 of that protein into a helical structure. This potentially also explains why the R7C/L12P double mutant does not interact with FliH (26). Furthermore, our work verifies and significantly extends preliminary yeast two-hybrid data reported for the H. pylori FliI/FliH interaction (12).

The FliI/FliH interaction was further analyzed by isolation and purification of the stable FliI-FliH complex by using gel filtration chromatography on mixtures of purified recombinant FliI-(2–91) and FliH-(117–258). The stoichiometry of the complex as determined by SDS-PAGE indicates an ~1:1 molar ratio of FliI-(2–91) and FliH-(117–258). The apparent molecular mass of this FliI-(2–91)-FliH-(117–258) complex is ~1.3 x 105 Da, indicating the subunit stoichiometry in the complex is different from the (FliH)2FliI stoichiometry reported for the full-length Salmonella FliI-FliH complex (24). Hence it appears that the N-domain of H. pylori FliI may also behave differently upon interacting with FliH. The functional significance of the FliI-(2–91)-FliH-(117–258) complex is presently unclear.

Data presented in this paper strongly support the contention that residues 1–14 of FliI form an amphipathic {alpha}-helix upon interaction with FliH. Most intriguingly, the related F1-ATPase {alpha}-subunit has been shown to contain an amphipathic {alpha}-helix at its N terminus, just preceding the {beta}-barrel domain (supplemental Fig. S1) (42). Furthermore, it is compelling that the F1-ATPase {alpha}-subunit uses the hydrophobic surface of this {alpha}-helix to facilitate protein/protein interactions with the F1-ATPase {delta}-subunit (42). With FliI, we have shown that hydrophobic residues on this presumed N-terminal helix mediate interactions with FliH. The F1-ATPase {delta}-subunit, in combination with the F0F1 b-subunit, is known to function as the stator of the F0F1-ATPase rotary motor, forming an elongated "outer stalk" and preventing unwanted rotation of the F1 catalytic subunits relative to the rotation of the torque-generating {gamma}-subunit (35, 42). We note that the b-subunit of F1-ATPase forms a highly elongated dimeric structure, again reminiscent of the elongated dimeric solution structure of Salmonella and presumably H. pylori FliH. The actual biological function of FliH in flagellar protein export is not known, although in vitro it acts as an inhibitor of FliI catalytic activity (26) and is also known to interact with membrane-embedded components of the flagellar export apparatus and anionic phospholipids (22, 25). Consistent with our observation of similarity in solution properties between FliH and the F0 F1-ATPase b-subunit, other authors have previously noted weak sequence similarity between a segment of the F0F1 b-subunit and FliH, suggesting the possibility of an evolutionary relationship between these proteins (43, 44). We suggest that the FliI/FliH interactions demonstrated in this report are analogous to the observed interactions between F1 {alpha}- and F1 {delta}-subunits in the F0F1-ATPase (42). This implies that the C-domain of FliH (like the F1 {delta}-subunit) would have a mostly globular structure responsible for interactions with FliI. Bioinformatic data indeed suggest that the C-domain of FliH adopts a globular structure.6

Previously published data support the idea that FliI functions as a hexameric ring structure (23). The nature of the FliI/FliH interaction and its uncanny similarity to the interaction between an amphipathic helix on the F1-ATPase {alpha}-subunit and a globular domain on the F1-ATPase {delta}-subunit lead us to suggest that FliH could function as the FliI stator. The overall structural features of FliH, a mostly helical N terminus and a globular C-domain together making up an elongated structure, are reminiscent of structural features of the F1-ATPase stator. Structural studies of H. pylori FliI and FliH are in progress in our laboratories to further elucidate the structure/function relationships of these proteins.


    FOOTNOTES
 
* This work was supported in part by an establishment grant (to S. A. M.) from the Saskatchewan Heath Research Foundation and a discovery grant from the National Sciences and Engineering Research Council of Canada. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{boxs} The on-line version of this article (available at http://www.jbc.org) contains Fig. S1 and Table S1. Back

1 Recipient of a Massey University doctoral scholarship. Back

2 To whom correspondence should be addressed: Dept. of Biochemistry, University of Saskatchewan, 107 Wiggins Rd., Saskatoon, Saskatchewan S7N 5E5, Canada. Tel.: 306-966-4381; Fax: 306-966-4390; E-mail: stan.moore{at}usask.ca.

3 The abbreviations used are: GST, glutathione S-transferase; PBS, phosphate-buffered saline; HSQC, heteronuclear single quantum coherence. Back

4 H. Iwai, M. Lane, and S. Moore, unpublished data. Back

5 M. Lane and S. Moore, unpublished results. Back

6 S. Moore, unpublished results. Back


    ACKNOWLEDGMENTS
 
We thank Stacey McDonald and George Wong for excellent technical assistance with cloning and protein purification. Dr. Hideo Iwai provided expertise in collecting the 15N-1H HSQC NMR spectra. We thank Dr. Yu Luo for reading the manuscript and for helpful discussions. Work in the laboratory at University College Cork was supported by the Irish Research Council for Science, Engineering, and Technology and by Science Foundation Ireland, and work in the laboratory in New Zealand was supported by the Palmerston North Medical Research Foundation.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Veldhuyzen van Zanten, S. J., and Sherman, P. M. (1994) Can. Med. Assoc. J. 150, 177-185[Abstract]
  2. Kuipers, E. J. J., Thijs, C., and Festen, H. P (1995) Aliment. Pharmacol. Ther. 9, Suppl. 2, 59-69
  3. The EUROGAST Study Group (1993) Lancet 341, 1359-1362; Correction (1993) Lancet 341, 1668[CrossRef][Medline] [Order article via Infotrieve]
  4. Parsonnet, J., Hansen, S., Rodriguez, L., Gelb, A. B., Warnke, R. A., Jellum, E., Orentreich, N., Vogelman, J. H., and Friedman, G. D. (1994) N. Engl. J. Med. 330, 1267-1271[Abstract/Free Full Text]
  5. Eaton, K., Morgan, D. R., and Krakowka, S. (1992) J. Med. Microbiol. 37, 123-127[Abstract]
  6. Kavermann, H., Burns, B. P., Angermuller, K., Odenbreit, S., Fischer, W., Melchers, K., and Haas, R. (2003) J. Exp. Med. 197, 813-822[Abstract/Free Full Text]
  7. Macnab, R. M. (2003) Annu. Rev. Microbiol. 57, 77-100[CrossRef][Medline] [Order article via Infotrieve]
  8. Macnab, R. M. (1996) in Escherichia coli and Salmonella: Cellular and Molecular Biology (Neidhardt F. C., ed) pp. 123-145, American Society for Microbiology, Washington, D. C.
  9. Tomb, J. F., White, O., Kerlavage, A. R., Clayton, R. A., Sutton, G. G., Fleischmann, R. D., Ketchum, K. A., Klenk, H. P., Gill, S., Dougherty, B. A., Nelson, K., Quackenbush, J., Zhou, L., Kirkness, E. F., Peterson, S., Loftus, B., Richardson, D., Dodson, R., Khalak, H. G., Glodek, A., McKenney, K., Fitzegerald, L. M., Lee, N., Adams, M. D., Hickey, E. K., Berg, D. E., Gocayne, J. D., Utterback, T. R., Peterson, J. D., Kelley, J. M., Cotton, M. D., Weidman, J. M., Fujii, C., Bowman, C., Watthey, L., Wallin, E., Hayes, W. S., Borodovsky, M., Karp, P. D., Smith, H. O., Fraser, C. M., and Venter, J. C. (1997) Nature 388, 539-547[CrossRef][Medline] [Order article via Infotrieve]
  10. O'Toole, P. W., Lane, M. C., and Porwollik, S. (2000) Microbes Infect. 2, 1207-1214[CrossRef][Medline] [Order article via Infotrieve]
  11. Niehus, E., Gressmann, H., Ye, F., Schlapbach, R., Dehio, M., Dehio, C., Stack, A., Meyer, T. F., Suerbaum, S., and Josenhans, C. (2004) Mol. Microbiol. 52, 947-961[CrossRef][Medline] [Order article via Infotrieve]
  12. Rain, J. C., Selig, L., De Reuse, H., Battaglia, V., Reverdy, C., Simon, S., Lenzen, G., Petel, F., Wojcik, J., Schachter, V., Chemama, Y., Labigne, A., and Legrain, P. (2001) Nature 409, 211-215[CrossRef][Medline] [Order article via Infotrieve]
  13. Galan, J. E., and Collmer, A. (1999) Science 284, 1322-1328[Abstract/Free Full Text]
  14. Kubori, T., Matsushima, Y., Nakamura, D., Uralil, J., Lara-Tejero, M., Sukhan, A., Galan, J. E., and Aizawa, S. I. (1998) Science 280, 602-605[Abstract/Free Full Text]
  15. Van Gijsegem, F., Gough, C., Zischek, C., Niqueux, E., Arlat, M., Genin, S., Barberis, P., German, S., Castello, P., and Boucher, C. (1995) Mol. Microbiol. 15, 1095-1114[CrossRef][Medline] [Order article via Infotrieve]
  16. Vogler, A. P., Homma, M., Irikura, V. M., and Macnab, R. M. (1991) J. Bacteriol. 173, 3564-3572[Abstract/Free Full Text]
  17. Eichelberg, K., Ginocchio, C. C., and Galan, J. E. (1994) J. Bacteriol. 176, 4501-4510[Abstract/Free Full Text]
  18. Stephens, C., Mohr, C., Boyd, C., Maddock, J., Gober, J., and Shapiro, L. (1997) J. Bacteriol. 179, 5355-5365[Abstract/Free Full Text]
  19. Porwollik, S., Noonan, B., and O'Toole, P. W. (1999) Infect. Immun. 67, 2060-2070[Abstract/Free Full Text]
  20. Pozidis, C., Chalkiadaki, A., Gomez-Serrano, A., Stahlberg, H., Brown, I., Tampakaki, A. P., Lustig, A., Sianidis, G., Politou, A. S., Engel, A., Panopoulos, N. J., Mansfield, J., Pugsley, A. P., Karamanou, S., and Economou, A. (2003) J. Biol. Chem. 278, 25816-25824[Abstract/Free Full Text]
  21. Akeda, Y., and Galan, J. E. (2004) J. Bacteriol. 186, 2402-2412[Abstract/Free Full Text]
  22. Auvray, F., Ozin, A. J., Claret, L., and Hughes, C. (2002) J. Mol. Biol. 318, 941-950[CrossRef][Medline] [Order article via Infotrieve]
  23. Claret, L., Calder, S. R., Higgins, M., and Hughes, C. (2003) Mol. Microbiol. 48, 1349-1355[CrossRef][Medline] [Order article via Infotrieve]
  24. Minamino, T., Tame, J. R. H., Namba, K., and Macnab, R. M. (2001) J. Mol. Biol. 312, 1027-1036[CrossRef][Medline] [Order article via Infotrieve]
  25. Minamino, T., and Macnab, R. M. (2000) Mol. Microbiol. 35, 1052-1064[CrossRef][Medline] [Order article via Infotrieve]
  26. Minamino, T., and Macnab, R. M. (2000) Mol. Microbiol. 37, 1491-1503
  27. Minamino, T., Gonzalez-Pedrajo, B., Oosawa, K., Namba, K., and Macnab, R. M. (2002) J. Mol. Biol. 322, 281-290[CrossRef][Medline] [Order article via Infotrieve]
  28. Gonzales-Pedrajo, B., Fraser, G. M., Minamino, T., and Macnab, R. M. (2002) Mol. Microbiol. 45, 967-982[CrossRef][Medline] [Order article via Infotrieve]
  29. Ryan, K. A., Karim, N., Worku, M., Penn, C. W., and O'Toole, P. W. (2005) J. Bacteriol. 187, 5742-5750[Abstract/Free Full Text]
  30. Ryan, K. A., Karim, N., Worku, M., Moore, S. A., Penn, C. W., and O'Toole, P. W. (2005) FEMS Microbiol. Lett. 248, 47-55[CrossRef][Medline] [Order article via Infotrieve]
  31. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) J. Mol. Biol. 215, 403-410[CrossRef][Medline] [Order article via Infotrieve]
  32. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. J. (1997) Nucleic Acids Res. 25, 3389-3402[Abstract/Free Full Text]
  33. Notredame, C., Higgins, D. G., and Heringa, J. (2000) J. Mol. Biol. 302, 205-217[CrossRef][Medline] [Order article via Infotrieve]
  34. Abrahams, J. P., Leslie, A. G. W., Lutter, R., and Walker, J. E. (1994) Nature 370, 621-628[CrossRef][Medline] [Order article via Infotrieve]
  35. Stock, D., Leslie, A. G. W., and Walker, J. E. (1999) Science 286, 1700-1705[Abstract/Free Full Text]
  36. Shirakihara, Y., Leslie, A. G., Abrahams, J. P., Walker, J. E., Ueda, T., Sekimoto, Y., Kambara, M., Saika, K., Kagawa, Y., and Yoshida, M. (1997) Structure (Camb.) 5, 825-836
  37. Collaborative Computational Project Number 4 (1994) Acta Crystallogr. Sect. D Biol. Crystallogr. 50, 760-763[CrossRef][Medline] [Order article via Infotrieve]
  38. Roussel, A., and Cambillau, C. (1991) TURBO-FRODO, Silicon Graphics Applications Directory, Silicon Graphics, Mountain View, CA
  39. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta Crystallogr. Sect. D Biol. Crystallogr. 54, 905-921[CrossRef][Medline] [Order article via Infotrieve]
  40. Rost, B., and Sander, C. (1993) J. Mol. Biol. 232, 584-599[CrossRef][Medline] [Order article via Infotrieve]
  41. Sambrook, J., and Russell, D. W. (2001) Molecular Cloning: A Laboratory Manual, 3rd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  42. Weber, J., Muharemagic, A., Wilke-Mounts, S., and Senior, A. E. (2004) J. Biol. Chem. 279, 25673-25679[Abstract/Free Full Text]
  43. Ge, Y., Old, I., Saint Girons, I., Yelton, D. B., and Charon, N. W (1996) Gene (Amst.) 168, 73-75[CrossRef][Medline] [Order article via Infotrieve]
  44. Jackson, M. W., and Plano, G. V. (2000) FEMS Microbiol Lett. 186, 85-90[CrossRef][Medline] [Order article via Infotrieve]
  45. Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 946-950[CrossRef]
  46. Merritt, E. A., and Bacon, D. J. (1997) Methods Enzymol. 277, 505-524[Medline] [Order article via Infotrieve]
  47. Nicholls, A., Sharp, K. A., and Honig, B. (1991) Proteins Struct. Funct. Genet. 11, 281-296[CrossRef][Medline]